Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

D
D’Souza, Jimson

GSK
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Jimson D’Souza
Favorite
Da Costa, Daniel

Day One Biopharmaceuticals
(P 08) PRELIMINARY CLINICAL ACTIVITY OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RAF FUSION-DRIVEN RECURRENT/PROGRESSIVE SARCOMAS
Daniel Da Costa
Favorite
D’Amato, Gina

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Gina D’Amato
Favorite
Dürr, Hans Roland

Orthopaedic Oncology, Department of Orthopaedics and Trauma Surgery, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Hans Roland Dürr
Favorite
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Hans Roland Dürr
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Hans Roland Dürr
Favorite
Díaz-Beveridge, Roberto

Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA
Roberto Díaz-Beveridge
Favorite
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
Roberto Díaz-Beveridge
Favorite
Díaz, Cristina

Hospital Clínico San Carlos
(P 515) ENDOBRONCHIAL NAVIGATION AS AN INTRAOPERATORY TOOL FOR RESECTION OF SMALL PULMONARY METASTASES IN SARCOMA PATIENTS
Cristina Díaz
Favorite
Dadia, Solomon

Tel Aviv Medical Center, Tel Aviv, Israel
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Solomon Dadia
Favorite
(P 319) HYPO-FRACTIONATED RADIATION THERAPY FOR THE EXTREMITY SOFT TISSUE SARCOM IN ELDERLY AND DISABLED.
Solomon Dadia
Favorite
Daffinoti, Anabela

University of Buenos Aires, Angel H Roffo Institute of Oncology
(P 460) IMPACT OF RESIDUAL TUMOR AFTER RE-EXCISION IN PATIENTS WITH PRIOR UNPLANNED RESECTION OF EXTREMITY AND TRUNK SOFT TISSUE SARCOMAS
Anabela Daffinoti
Favorite
DaFonseca, Manuel

Sonnet BioTherapeutics
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Manuel DaFonseca
Favorite
Daghistani, Doured

Miami Cancer Institute
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Doured Daghistani
Favorite
Dahan, Gal

Tel Aviv Medical Center
(P 240) IDENTIFYING PATIENTS AT HIGH RISK OF HIP FRACTURE DUE TO BONE TUMORS BY COMPUTATIONAL BIOMECHANICS: A RANDOMIZED PROSPECTIVE CLINICAL STUDY
Gal Dahan
Favorite
Dai, Dong

Daiichi Sankyo, Inc.
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Dong Dai
Favorite
Dallaire, Frédérick

Polytechnique Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Frédérick Dallaire
Favorite
Dall'Igna, Patrizia

Department of Precision and Regenerative Medicine and Jonic Area,Pediatric Hospital Giovanni XXIII, University of Bari
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Patrizia Dall'Igna
Favorite
D'Amato, Gina

Sylvester Comprehensive Cancer Center
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Gina D'Amato
Favorite
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Gina D'Amato
Favorite
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Gina D'Amato
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Gina D'Amato
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Gina D'Amato
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Gina D'Amato
Favorite
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Gina D'Amato
Favorite
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Gina D'Amato
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Gina D'Amato
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Gina D'Amato
Favorite
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Gina D'Amato
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Gina D'Amato
Favorite
D'Amato, Vittoria

IRCCS Humanitas Research Hospital
(P 327) LEARNING CURVE ANALYSIS IN RETROPERITONEAL SARCOMA SURGERY
Vittoria D'Amato
Favorite
(P 457) LONG-TERM FOLLOW-UP OF PATIENTS WITH ATYPICAL LIPOMATOUS TUMOR (ALT) TREATED WITH MARGINAL RESECTION IN A REFERRAL CENTER
Vittoria D'Amato
Favorite
D'Ambrosio, Lorenzo

University if Turin, Turin, Italy
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Lorenzo D'Ambrosio
Favorite
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Lorenzo D'Ambrosio
Favorite
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Lorenzo D'Ambrosio
Favorite
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Lorenzo D'Ambrosio
Favorite
(P 455) EXTRASKELETAL EWING SARCOMA: A MULTICENTRIC RETROSPECTIVE STUDY FROM THE ITALIAN SARCOMA GROUP
Lorenzo D'Ambrosio
Favorite
Dandis, Rana

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Rana Dandis
Favorite
D'Angelo, Sandra

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Sandra D'Angelo
Favorite
(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO
Sandra D'Angelo
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Sandra D'Angelo
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Sandra D'Angelo
Favorite
Danieau, Geoffroy

Research Institute of the McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Geoffroy Danieau
Favorite
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Geoffroy Danieau
Favorite
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Geoffroy Danieau
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Geoffroy Danieau
Favorite
DANNEPOND, Antoine

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Antoine DANNEPOND
Favorite
Daolio, Primo Andrea

ASST Gaetano Pini - CTO
(P 431) TREATMENT STRATEGY AND PROGNOSTIC FACTORS IN EXTRASKELETAL EWING SARCOMA: AN INSTITUTIONAL RETROSPECTIVE ANALYSIS
Primo Andrea Daolio
Favorite
Darbo, Elodie

Université de Bordeaux
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Elodie Darbo
Favorite
Dasgupta, Roshni

Cincinnati Children's Hospital Medical Center
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Roshni Dasgupta
Favorite
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Roshni Dasgupta
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Roshni Dasgupta
Favorite
Daud, Layla

Indiana University
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Layla Daud
Favorite
Davick, Jonathan

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Jonathan Davick
Favorite
David, Bruna

Instituto Nacional de Câncer
(P 142) THE SARCOMA EUROPEAN AND LATIN AMERICAN NETWORK (SELNET) PROJECT: OVERVIEW OF THE MAIN RESULTS OF THE SELNET REGISTRY
Bruna David
Favorite
Davies, Christopher

University College London, Cancer Institute
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Christopher Davies
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Christopher Davies
Favorite
Davies, Kurtis

University of Colorado - Anschutz Medical Campus
(P 237) SECONDARY REARRANGEMENT CREATING A PLEC-EML4-ALK DOUBLE FUSION AS A MECHANISM OF RESISTANCE TO CRIZOTINIB IN AN EML4-ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR
Kurtis Davies
Favorite
Davis, Alison

Canberra hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Alison Davis
Favorite
Davis, Elizabeth

Vanderbilt University Medical Center
(P 160) A PROSPECTIVE STUDY EVALUATING THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH ACTIVITY LEVEL AND SLEEP PATTERNS IN SARCOMA SURVIVORS
Elizabeth Davis
Favorite
(P 207) A MULTICENTER PHASE II STUDY OF CABOZANTINIB PLUS NIVOLUMAB FOR PATIENTS WITH ADVANCED ANGIOSARCOMA PREVIOUSLY TREATED WITH A TAXANE: ALLIANCE A091902
Elizabeth Davis
Favorite
(P 210) FINANCIAL TOXICITY ASSOCIATED WITH THE TREATMENT OF SARCOMAS: A SINGLE INSTITUTION RETROSPECTIVE-PROSPECTIVE STUDY
Elizabeth Davis
Favorite
(P 211) AN ANALYSIS OF SELF-REPORTED DEPRESSION IN SARCOMA PATIENTS
Elizabeth Davis
Favorite
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Elizabeth Davis
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Elizabeth Davis
Favorite
Davis, Jeremy

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Jeremy Davis
Favorite
Davis, Jessica

Indiana University
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Jessica Davis
Favorite
Davis, Lara

OHSU Knight Cancer Institute
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Lara Davis
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Lara Davis
Favorite
(P 191) SARC024 COHORT D: PHASE 2 TRIAL OF REGORAFENIB IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RHABDOMYOSARCOMA
Lara Davis
Favorite
(P 341) A PHASE 1B STUDY TO EVALUATE PREOPERATIVE ERIBULIN IN COMBINATION WITH RADIATION IN RETROPERITONEAL SARCOMA
Lara Davis
Favorite
Davison, Zoe

Bone Cancer Research Trust
(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS
Zoe Davison
Favorite
Daw, Najat

MD Anderson Cancer Center
(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA
Najat Daw
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Najat Daw
Favorite
Dawo, Sallu

Northern Bone and Soft Tissue Tumour Service
(P 522) FLUORESCENCE GUIDED SURGERY WITH INDOCYANINE GREEN FOR SURGICAL RESECTION OF METASTATIC BONE AND SOFT TISSUE TUMOURS: A CASE SERIES
Sallu Dawo
Favorite
de Albert, Matias

Hospital Valle de Hebron
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Matias de Albert
Favorite
De Benedictis, Ilaria

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Ilaria De Benedictis
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Ilaria De Benedictis
Favorite
de Boed, Ella

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 251) EVALUATION OF POTENTIAL TARGETS FOR FLUORESCENCE-GUIDED SURGERY IN PEDIATRIC EWING SARCOMA: A PRECLINICAL PROOF-OF-CONCEPT STUDY
Ella de Boed
Favorite
De Carli, Emilie

Pediatric hospital of the University
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Emilie De Carli
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Emilie De Carli
Favorite
De Cecco, Loris

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 363) Β-CATENIN MUTATIONS AND TRANSCRIPTOMIC REPROGRAMMING IN DESMOID FIBROMATOSIS (DF)
Loris De Cecco
Favorite
De Cock, Lore

Department of General Medical Oncology, University Hospitals Leuven and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Lore De Cock
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Lore De Cock
Favorite
(P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY
Lore De Cock
Favorite
(P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT
Lore De Cock
Favorite
(P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES
Lore De Cock
Favorite
De Donno, Giulia

Image Sciences Institute, UMC Utrecht
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Giulia De Donno
Favorite
De La Cuesta, Esther

Bayer HealthCare Pharmaceuticals, Inc.
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Esther De La Cuesta
Favorite
De Luca, Alberto

Image Sciences Institute, UMC Utrecht
(P 229) ON THE VARIABILITY IN THE ANALYSIS OF APPARENT DIFFUSION COEFFICIENT ESTIMATES FOR MULTICENTER DIFFUSION MRI DATA OF RHABDOMYOSARCOMA PATIENTS
Alberto De Luca
Favorite
De Luca, Ida

Policlinico P Giaccone
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Ida De Luca
Favorite
De Mattia, Aurora

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Laboratorio di Controllo di Prodotti Biologici, Centro di Referenza Nazionale per i Metodi Alternativi, Benessere e Cura degli Animali da Laboratorio
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Aurora De Mattia
Favorite
De Mattos, Camila

Skåne University Hospital
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Camila De Mattos
Favorite
De Meo, Simone

Fondazione per la ricerca sui tumori dell'apparato muscoloscheletrico e rari Onlus
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Simone De Meo
Favorite
de Miranda, Noel

LUMC
(P 368) DECODING THE IMMUNOGENOMIC DETERMINANTS OF RADIOTHERAPY RESPONSE IN SOFT TISSUE SARCOMAS
Noel de Miranda
Favorite
(P 369) MAGEA ANTIGENS AS IMMUNOTHERAPEUTIC TARGETS FOR ADVANCED OSTEOSARCOMA
Noel de Miranda
Favorite
De Rosa, francesco

Irst
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
francesco De Rosa
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
francesco De Rosa
Favorite
De Sutter, Luna

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Luna De Sutter
Favorite
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Luna De Sutter
Favorite
De Toni, Chiara

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Chiara De Toni
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Chiara De Toni
Favorite
De Vita, Alessandro

Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 37) DISSECTING THE ROLE OF EXTRACELLULAR VESICLES IN THE MANAGEMENT OF GIST
Alessandro De Vita
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Alessandro De Vita
Favorite
(P 364) EVALUATION OF THE PREDICTIVE ROLE OF SYSTEMIC AND INTRATUMORAL IMMUNITY IN PATIENTS WITH LOCALIZED LIPOSARCOMAS, MYXOFIBROSARCOMAS AND UNDIFFERENTIATED PLEOMORPHIS SARCOMAS
Alessandro De Vita
Favorite
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Alessandro De Vita
Favorite
de Vries, Isabelle

Princess Maxima Center for Pediatric Oncology
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Isabelle de Vries
Favorite
De Wever, Olivier

Ghent University
(P 291) DEVELOPMENT OF A LIVE TISSUE SARCOMA BIOBANK TO SUPPORT THE CREATION OF PATIENT-DERIVED TRANSLATIONAL MODELS
Olivier De Wever
Favorite
(P 295) ORTHOTOPIC XENOGRAFTS OF PAIRED SARCOMA PRIMARY TUMOUR, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY IN A MINIMAL RESIDUAL DISEASE MODEL
Olivier De Wever
Favorite
(P 296) EX VIVO SARCOMA CELL CULTURES FROM PAIRED PRIMARY, LOCAL RELAPSE AND METASTATIC SITES REVEALS PHENOTYPIC HETEROGENEITY
Olivier De Wever
Favorite
Defachelles, Anne-Sophie

Centre Oscar Lambret
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Anne-Sophie Defachelles
Favorite
Dehner, Carina

Indiana University
(P 274) TYK2 AND MEK COMBINATION THERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS AND OTHER SOFT TISSUE SARCOMAS
Carina Dehner
Favorite
Dei Tos, Angelo Paolo

Department of Medicine, University of Padua School of Medicine, Padova, Italy
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Angelo Paolo Dei Tos
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Angelo Paolo Dei Tos
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Angelo Paolo Dei Tos
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Angelo Paolo Dei Tos
Favorite
Del Monte, Francesca

Nuovo Ospedale Santo Stefano
(P 144) IMPLEMENTATION OF THE EUROPEAN CLINICAL TRIAL REGULATION: SURVEY OF THE ITALIAN SARCOMA GROUP CENTERS
Francesca Del Monte
Favorite
Del Savio, Elisa

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Elisa Del Savio
Favorite
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Elisa Del Savio
Favorite
Dela Cruz, Filemon

Memorial Sloan Kettering Cancer Center
(P 289) IDENTIFICATION OF EFFECTIVE THERAPEUTIC COMBINATIONS WITH THE NUCLEAR EXPORT PROTEIN INHIBITOR, SELINEXOR, IN PEDIATRIC SOLID TUMORS
Filemon Dela Cruz
Favorite
Delaney, Thomas

Massachusetts General Hospital
(P 338) PREOPERATIVE RADIATION THERAPY IS NOT ASSOCIATED WITH ADVERSE POSTOPERATIVE OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA
Thomas Delaney
Favorite
Delattre, Olivier

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Olivier Delattre
Favorite
Delespaul, Lucile

Cancer Research Center of Toulouse
(P 268) IMPACT OF CELLULAR FUSION IN THE ONCOGENESIS OF LEIOMYOSARCOMAS
Lucile Delespaul
Favorite
Demetri, George

IDRx, Inc
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
George Demetri
Favorite
Demeulemeester, Jonas

VIB-KU Leuven Center for Cancer Biology
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Jonas Demeulemeester
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Jonas Demeulemeester
Favorite
Demicco, Elizabeth

Sinai Health System
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Elizabeth Demicco
Favorite
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
Elizabeth Demicco
Favorite
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Elizabeth Demicco
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Elizabeth Demicco
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Elizabeth Demicco
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Elizabeth Demicco
Favorite
den Hollander, Dide

Radboud University Medical Center
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Dide den Hollander
Favorite
DeNardo, Bradley

Lifespan
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Bradley DeNardo
Favorite
Denecke, Barbara

Kantonsspital St. Gallen
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Barbara Denecke
Favorite
Deng, Lichun

Department of Oncology, The Affiliated Jiangyin Hospital of Nantong University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Lichun Deng
Favorite
(P 48) SIGNIFICANCE OF MONITORING PLASMA CONCENTRATION OF RIPRETINIB IN CHINESE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Lichun Deng
Favorite
Deng, Mengying

Division of Biostatistics and Bioinformatics, Fox Chase Cancer Center
(P 152) EVALUATING DIAGNOSTIC APPROACHES TO DERMATOFIBROSARCOMA PROTUBERANS: AN OPPORTUNITY TO REDUCE THE NUMBER OF INTERVENTIONS
Mengying Deng
Favorite
Deng, Ting

Department of gastrointestinal medical oncology,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 42) THE EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A SINGLE-INSTITUTION ANALYSIS
Ting Deng
Favorite
Deng, Xuemei

Seattle Children's Hospital
(P 448) CAF-LIKE EWING SARCOMA CELLS DEPOSIT PRO-TUMORIGENIC EXTRACELLULAR MATRIX IN RESPONSE TO TGF-BETA SIGNALING
Xuemei Deng
Favorite
Denschlag, Dominik

Hochtaunus Klinik
(P 133) TEN RECOMMENDATIONTS FOR SARCOMA SURGERY: CONSENSUS OF THE SURGICAL SOCIETIES BASED ON THE GERMAN S3 GUIDELINE "ADULT SOFT TISSUE SARCOMA"
Dominik Denschlag
Favorite
Denu, Ryan

MD Anderson Cancer Center
(P 36) CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS
Ryan Denu
Favorite
(P 83) CLINICO-GENOMIC PROFILING OF CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMAS REVEALS TP53 MUTATION TO BE ASSOCIATED WITH WORSE OUTCOMES
Ryan Denu
Favorite
(P 198) PERSONALIZED MULTIDISCIPLINARY MANAGEMENT OF SARCOMA IN PATIENTS WITH LYNCH SYNDROME
Ryan Denu
Favorite
(P 360) TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE
Ryan Denu
Favorite
(P 400) THE LANDSCAPE OF GENOMIC ALTERATIONS FROM 1494 SOFT TISSUE AND BONE SARCOMAS AT MD ANDERSON CANCER CENTER
Ryan Denu
Favorite
Deobald, Ray

University of Saskatchewan
(P 148) MOVING TOWARDS THE OPTIMIZATION OF DIAGNOSIS FOR PATIENTS WITH SARCOMA: A 10-YEAR REVIEW OF EXTERNALLY CONSULTED SARCOMA CASES IN A GENERAL ANATOMICAL PATHOLOGY SERVICE
Ray Deobald
Favorite
Dercle, Laurent

Radiology, New York-Presbyterian/Columbia University Medical Center
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Laurent Dercle
Favorite
Desai, Jayesh

Peter MacCallum Cancer Centre
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
Jayesh Desai
Favorite
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Jayesh Desai
Favorite
Desai, Sharvil

Levine Cancer Institute
(P 258) THE CRITICALITY OF OXIDATIVE PHOSPHORYLATION IN SYNOVIAL SARCOMA METASTASIS
Sharvil Desai
Favorite
Desar, Ingrid M.

Radboud University Medical Center
(P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST
Ingrid M. Desar
Favorite
(P 30) FINANCIAL DIFFICULTIES EXPERIENCED BY DUTCH GASTROINTESTINAL STROMAL TUMOR (GIST) PATIENTS: DATA FROM A CROSS-SECTIONAL MULTICENTER STUDY
Ingrid M. Desar
Favorite
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Ingrid M. Desar
Favorite
Deshpande, Hari

Yale University
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Hari Deshpande
Favorite
DESOLNEUX, Grégoire

Oncological department of Institut Bergonié
(P 521) HOW TO MANAGE ABDOMINAL PARIETECTOMY, REVIEW OF EXPERIENCE IN INSTITUT BERGONIE
Grégoire DESOLNEUX
Favorite
Devalck, Christine

Department Hematology Oncology, HUDERF, ULB, HUB, Brussels, Belgium
(P 209) PROGNOSTIC VALUE OF EARLY RADIOLOGIC TUMOUR VOLUME RESPONSE IN RHABDOMYOSARCOMA; RESULTS OF THE EUROPEAN PAEDIATRIC SOFT TISSUE SARCOMA STUDY GROUP RMS 2005 STUDY
Christine Devalck
Favorite
Devaud, Nicolas

Instituto Oncologico Fundacion Arturo Lopez Perez (FALP)
(P 330) TREATMENT VARIATIONS, OUTCOMES AND PATTERNS OF RECURRENCE AFTER CURATIVE INTENT TREATMENT FOR PRIMARY RETROPERITONEAL SARCOMAS IN LATIN AMERICA. FIRST COLLABORATIVE LATAMSARC STUDY
Nicolas Devaud
Favorite
Deville, Curtiland

Johns Hopkins University School of Medicine
(P 559) PROSPECTIVE PHASE II TRIAL OF PREOPERATIVE HYPOFRACTIONATED PROTON THERAPY FOR EXTREMITY AND TRUNCAL AND TRUNCAL SOFT TISSUE SARCOMA: THE PRONTO STUDY RATIONALE AND DESIGN
Curtiland Deville
Favorite
Dexter, Susan

Sonnet BioTherapeutics
(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS
Susan Dexter
Favorite
Dharmani, Charles

Daiichi Sankyo Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Charles Dharmani
Favorite
Dharmani, Charles

Daiichi Sankyo, Inc.
(P 199) PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 3-YEAR SAFETY DATA ASSESSMENT
Charles Dharmani
Favorite
(P 200) EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES
Charles Dharmani
Favorite
Dharmani, Charles

Daiichi Sankyo Inc.
(P 200) EPIDEMIOLOGY OF TENOSYNOVIAL GIANT CELL TUMOR IN THE UNITED STATES
Charles Dharmani
Favorite
Dhir, Aditi

University of Miami Miller School of Medicine
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Aditi Dhir
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Aditi Dhir
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Aditi Dhir
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Aditi Dhir
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Aditi Dhir
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Aditi Dhir
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Aditi Dhir
Favorite
Dhupar, Rajeev

University of Pittsburgh Medical Center
(P 466) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Rajeev Dhupar
Favorite
(P 544) INTRAOPERATIVE EVALUATION OF BONE AND SOFT TISSUE SARCOMA SURGICAL MARGINS WITH INDOCYANINE GREEN FLUORESCENCE IMAGING
Rajeev Dhupar
Favorite
Di Carlo, Daniela

University Hospital of Padova
(P 202) INFLAMMATORY MYOFIBROBLASTIC TUMOUR WITH ROS1 GENE FUSIONS IN CHILDREN AND YOUNG ADOLESCENTS
Daniela Di Carlo
Favorite
Di Cecco, Fabio

Ospedale Morgagni Pierantoni
(P 533) SAFETY AND PRELIMINARY BIOLOGICAL ACTIVITY OF A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION IN SARCOMAS.
Fabio Di Cecco
Favorite
Di Gioia, Dorit

Department of Medicine III, LMU University Hospital, LMU Munich
(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)
Dorit Di Gioia
Favorite
(P 530) FIH PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF THE001 COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Dorit Di Gioia
Favorite
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Dorit Di Gioia
Favorite
Di Lernia, Davide

Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),
(P 270) ALTERNATIVE SPLICING (AS) REGULATION AS A NOVEL THERAPEUTIC TARGET IN SOFT-TISSUE SARCOMA (STS)
Davide Di Lernia
Favorite
(P 279) PROTEIN PHOSPHATASE 2 A INHIBITION AS A MECHANISM TO ENHANCE DOXORUBICIN ACTIVITY
Davide Di Lernia
Favorite
Di Maggio, Antonio

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Antonio Di Maggio
Favorite
Di Mauro, Pierluigi

ASST Spedali Civili di Brescia
(P 159) IN BETWEEN OF LYMPHOMAS AND SARCOMAS: WHERE DO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS (HDCN) STAND? A RETROSPECTIVE, MULTI-INSTITUTIONAL STUDY FROM THE ITALIAN SARCOMA GROUP (ISG)
Pierluigi Di Mauro
Favorite
Diallo, Jean-Simon

The Ottawa Hospital Research Institute
(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA
Jean-Simon Diallo
Favorite
Diamond, Mark

University of Pennsylvania-Abramson Cancer Center
(P 552) RANDOMIZED PHASE II TRIAL OF CABOZANTINIB COMBINED WITH PD-1 AND CTLA-4 INHIBITION VERSUS CABOZANTINIB IN METASTATIC SOFT TISSUE SARCOMA.
Mark Diamond
Favorite
Díaz-Martín, Juan

Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla, 41013 Seville, Spain.
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Juan Díaz-Martín
Favorite
Dibs, Khaled

Ohio State University Wexner Medical Center
(P 315) SCALP VOLUMETRIC MODULATED ARC THERAPY USING 3D MILLED BOLUS: DOSIMITRY, TOXICITY AND OUTCOMES
Khaled Dibs
Favorite
Dickson, Brendan

Sinai Health System
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Brendan Dickson
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Brendan Dickson
Favorite
(P 421) USING TRANSCRIPTOMICS TO IDENTIFY LEIOMYOSARCOMA PATIENTS AT RISK OF METASTASIS
Brendan Dickson
Favorite
Dickson, Mark

MSKCC
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
Mark Dickson
Favorite
Dieckmann, Nils

University Hospital Essen, West German Cancer Center
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Nils Dieckmann
Favorite
Dierselhuis, Miranda

Prinses Maxima Centrum
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Miranda Dierselhuis
Favorite
Dietz, Matthew

University of Utah, Primary Children's Hospital
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Matthew Dietz
Favorite
Difilippo, Valeria

Lund University
(P 230) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Valeria Difilippo
Favorite
(P 371) DISRUPTION OF THE TP53 LOCUS IN OSTEOSARCOMA LEADS TO TP53 PROMOTER GENE FUSIONS AND RESTORATION OF PARTS OF THE TP53 SIGNALLING PATHWAY
Valeria Difilippo
Favorite
Difrancesco, Lisa

University of Calgary
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Lisa Difrancesco
Favorite
Digklia, Antonia

Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION
Antonia Digklia
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Antonia Digklia
Favorite
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Antonia Digklia
Favorite
Dileo, Palma

University College Hospital
(P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)
Palma Dileo
Favorite
(P 342) THE EVALUATION AND OUTCOMES OF MESENTERIC AND INTRA-ABDOMINAL DESMOIDS: A TARPSWG STUDY
Palma Dileo
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Palma Dileo
Favorite
di, maojun

Department of Gastrointestinal Surgery, Taihe Hospital，Hubei University of Medicine
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
maojun di
Favorite
Ding, Li

Aadi Bioscience
(P 540) PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 AND TSC2 (PRECISION I)
Li Ding
Favorite
Ding, Yuqi

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Yuqi Ding
Favorite
Dirksen, Uta

University Hospital Essen, Pediatrics III, West German Cancer Center, German Cancer Research Center (DKTK) site Essen, National Center for Tumordiseases (NCT) site Essen, ,
(P 17) METASTASIS-SPECIFIC GENE EXPRESSION PATTERNS IN EWING SARCOMA
Uta Dirksen
Favorite
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Uta Dirksen
Favorite
(P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS
Uta Dirksen
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Uta Dirksen
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Uta Dirksen
Favorite
Divenko, Margarita

Baylor College of Medicine
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Margarita Divenko
Favorite
Dizon, Don

Brown University
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Don Dizon
Favorite
Dlugosz, Andrzej

University of Michigan
(P 293) GENERATION OF A SPONTANEOUS IMMUNOCOMPETENT MOUSE MODEL OF LIPOSARCOMA
Andrzej Dlugosz
Favorite
Dodd, Rebecca

University of Iowa
(P 286) EPIGENETIC MECHANISMS AND SIGNATURES OF SARCOMA PROGRESSION AND METASTASIS
Rebecca Dodd
Favorite
Dodoo, Christopher

Mayo Clinic Arizona
(P 312) MANAGEMENT OF ADULT HEAD AND NECK SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Christopher Dodoo
Favorite
Doherty, Mark

St Vincents University Hospital
(P 155) THE IMPACT OF THE ROLE OF A SARCOMA ADVANCED NURSE PRACTITIONER (ANP) BIOPSY CLINIC IN IMPROVING PATIENT ACCESS TO SARCOMA SERVICES
Mark Doherty
Favorite
(P 156) PATIENT REPORTED EXPERIENCES WITHIN THE IRISH SARCOMA GROUP
Mark Doherty
Favorite
(P 213) EXPERIENCE WITH THE USE OF TRABECTEDIN IN ADVANCED SOFT TISSUE SARCOMA IN IRELAND
Mark Doherty
Favorite
(P 217) CONTEMPORARY TREATMENT PATTERNS AND OUTCOMES IN THE MANAGEMENT OF ANGIOSARCOMA IN IRELAND
Mark Doherty
Favorite
Doherty, Terrence

Moores Cancer Center, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Terrence Doherty
Favorite
Dolado, Maria Carmen

HU Canarias
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Maria Carmen Dolado
Favorite
Dolcan, Ana

CHUV
(P 535) THERAGNOSTICS IN SOFT TISSUE SARCOMA USING A VASCULAR DISCRUPTION APPROACH
Ana Dolcan
Favorite
Donati, Davide

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Davide Donati
Favorite
Donati, Davide Maria

Istituto Ortopedico Rizzoli IOR IRCCS, SC Third Orthopaedic Clinic and Traumatology, Bologna Italy
(P 01) EXTRASKELETAL EWING SARCOMA OF THE EXTREMITIES AND TRUNK IN < 25 YEARS OLD PATIENTS: A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES.
Davide Maria Donati
Favorite
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Davide Maria Donati
Favorite
(P 253) THE EFFICACY OF MEDICATED PATCHES IN SOFT TISSUE SARCOMAS: IN-VITRO AND EX-VIVO VALIDATION.
Davide Maria Donati
Favorite
(P 355) FUSION TRANSCRIPTOME PROFILING DEFINES THE MONOCLONAL NATURE OF MULTIFOCAL EPITHELIOID HEMANGIOMA OF BONE
Davide Maria Donati
Favorite
Dong, Qun

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Qun Dong
Favorite
Dong, Yang

Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Yang Dong
Favorite
Dong, Zhi

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 46) CIRCULATING TUMOR DNA (CTDNA) ANALYSES AND RESISTANCE MECHANISMS EXPLORATION OF KIT-MUTANT GASTROINTESTINAL STROMAL TUMORS (GISTS) TREATED WITH AVAPRITINIB OR RIPRETINB
Zhi Dong
Favorite
Doni, Michele

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Michele Doni
Favorite
Donini, Chiara

Department of Oncology, University of Turin
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Chiara Donini
Favorite
Donovan Bailey, Swneke

McGill University
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Swneke Donovan Bailey
Favorite
(P 434) MECHANISMS OF CHEMORESISTANCE IN CIC-DUX4 SARCOMA AS DETERMINED BY IN VIVO FUNCTIONAL GENOMICS
Swneke Donovan Bailey
Favorite
Dontenwill, Monique

UMR CNRS 7021
(P 277) ANTI-GD2 SYNERGIZES WITH HYPOXIA PATHWAY TARGETING TO BLOCK OSTEOSARCOMA CELL PROLIFERATION AND MIGRATION.
Monique Dontenwill
Favorite
(P 389) OSTEOBLASTIC-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMA (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 PROTOCOL.
Monique Dontenwill
Favorite
Dorand, Dixon

Tennessee Oncology
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Dixon Dorand
Favorite
(P 380) NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES
Dixon Dorand
Favorite
D'Orazio, Federico

Humanitas Research Hospital
(P 433) A 20-YEAR MONOCENTER EXPERIENCE ON CLINICAL CHARACTERISTICS AND OUTCOME OF EXTRASKELETAL EWING SARCOMA.
Federico D'Orazio
Favorite
Dore-Smith, Emily

University College London
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Emily Dore-Smith
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Emily Dore-Smith
Favorite
Doronzo, Gabriella

Department of Oncology, University of Turin
(P 262) ESTABLISHMENT AND CHARACTERIZATION OF THE FIRST RADIATION-INDUCED, PATIENT-DERIVED ANGIOSARCOMA CELL LINE
Gabriella Doronzo
Favorite
Dorsey*, Jen

Lunenfeld Tanenbaum Research Institute/Mount Sinai Hospital
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Jen Dorsey*
Favorite
(P 265) SELECTIVE TARGETING OF BET FAMILY EPIGENETIC REGULATORS IN ADVANCED AND METASTATIC ALVEOLAR RHABDOMYOSARCOMA
Jen Dorsey*
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Jen Dorsey*
Favorite
Dotti, Gianpietro

UNC Lineberger Comprehensive Cancer Center
(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA
Gianpietro Dotti
Favorite
Dotti, Silvia

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Laboratorio di Controllo di Prodotti Biologici, Centro di Referenza Nazionale per i Metodi Alternativi, Benessere e Cura degli Animali da Laboratorio, 25124 Brescia
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Silvia Dotti
Favorite
Doung, Yee-Cheen

Oregon Health & Science University
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Yee-Cheen Doung
Favorite
(P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS
Yee-Cheen Doung
Favorite
(P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS
Yee-Cheen Doung
Favorite
(P 227) DE NOVO NATURAL LANGUAGE PROCESSING (NLP) ALGORITHM ACCURATELY IDENTIFIES MYXOFIBROSARCOMA DIRECTLY FROM PATHOLOGY REPORTS
Yee-Cheen Doung
Favorite
(P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION
Yee-Cheen Doung
Favorite
(P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE
Yee-Cheen Doung
Favorite
Doval, Anxela

HU Clínico San Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Anxela Doval
Favorite
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Anxela Doval
Favorite
Doyon, Josee

CIUSSS Est-de-l'Île-de-Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Josee Doyon
Favorite
Drabbe, Cas

Netherlands Cancer Institute
(P 140) THE PRE-DIAGNOSTIC GENERAL PRACTIONER JOURNEY OF SARCOMA PATIENTS: A REAL-WORLD DATA STUDY.
Cas Drabbe
Favorite
Drake, James

Hospital for Sick Children
(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA
James Drake
Favorite
Drapeau, Isabelle

CIUSSS Est-de-l'Île-de-Montréal
(P 134) IMPACT OF THE PARTNERSHIP BETWEEN TERTIARY CENTERS AND NON-SARCOMA RADIOLOGY CENTERS.
Isabelle Drapeau
Favorite
Drilon, Alexander

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Alexander Drilon
Favorite
Droste, Margret

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR
Margret Droste
Favorite
Druta, Mihaela

H. Lee Moffitt Cancer Center and Research Institute
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Mihaela Druta
Favorite
Dry, Sarah

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Sarah Dry
Favorite
D'Silva, Dhiren

PTC Therapeutics, Inc.
(P 182) UPDATED RESULTS FROM AN ONGOING PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA
Dhiren D'Silva
Favorite
(P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)
Dhiren D'Silva
Favorite
Duan, Zhenfeng

University of Miami
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Zhenfeng Duan
Favorite
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Zhenfeng Duan
Favorite
Duarte-Bateman, Daniela

Cleveland Clinic
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Daniela Duarte-Bateman
Favorite
Dubois, Steven

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
(P 03) EVOLUTION OF CLINICALLY ACTIONABLE VARIANTS IN ADVANCED PEDIATRIC AND AYA BONE SARCOMAS
Steven Dubois
Favorite
(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
Steven Dubois
Favorite
(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE
Steven Dubois
Favorite
(P 161) EFFICACY, SAFETY, AND TREATMENT HOLD WAIT-AND-SEE OUTCOMES OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Steven Dubois
Favorite
(P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT
Steven Dubois
Favorite
Duc, Adeline

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Adeline Duc
Favorite
Ducassou, Anne

OCR
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Anne Ducassou
Favorite
Ducassou, Stephane

Pediatric Hospital
(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY
Stephane Ducassou
Favorite
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Stephane Ducassou
Favorite
Ducceschi, Monika

INT Milan
(P 328) REAL-LIFE EXPERIENCE OF PAZOPANIB IN PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA (U-LMS) FROM TWO REFERRAL ITALIAN CENTERS
Monika Ducceschi
Favorite
ducimetiere, francoise

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
francoise ducimetiere
Favorite
Duensing, Anette

University of Pittsburgh School of Medicine
(P 373) DEDIFFERENTIATED AND HIGH GRADE CHONDROSARCOMAS: HOW DOES ISOCITRATE DEHYDROGENASE STATUS APPRISE PROGNOSIS AND THERAPY?
Anette Duensing
Favorite
Dufresne, Armelle

CENTRE LEON BERARD
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Armelle Dufresne
Favorite
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Armelle Dufresne
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Armelle Dufresne
Favorite
Dulude, Jean-Philippe

Université de Montréal
(P 245) IN VIVO USE OF RAMAN SPECTROSCOPY IN SOFT TISSUE SARCOMA RESECTION
Jean-Philippe Dulude
Favorite
Dumanian, Gregory

Northwestern Medicine
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Gregory Dumanian
Favorite
Duncan, Aundrietta

Salarius Pharmaceuticals
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Aundrietta Duncan
Favorite
Dunham, Alden

Vanderbilt University Medical Center
(P 218) NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS
Alden Dunham
Favorite
Dunlop, Hayley

The Ohio State University College of Medicine
(P 314) PRE-OPERATIVE RADIATION THERAPY INCREASES ADHERENCE IN PATIENTS WITH HIGH-RISK EXTREMITY SOFT TISSUE SARCOMA
Hayley Dunlop
Favorite
Duran Sierra, Elvis

MD Anderson Cancer Center
(P 221) EARLY RESULTS IN NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING IN THE ASSESSMENT OF RESPONSE AND PROGRESSION IN DESMOID FIBROMATOSIS: PILOT STUDY IN A SPECIALIZED CANCER INSTITUTION
Elvis Duran Sierra
Favorite
(P 239) CANCER RADIOMIC AND PERFUSION IMAGING (CARPI) AUTOMATED FRAMEWORK: VALIDATION ON MUSCULOSKELETAL TUMORS IN A SPECIALIZED CANCER CENTER
Elvis Duran Sierra
Favorite
(P 354) ROLE OF APPARENT DIFFUSION COEFFICIENT (ADC) MAP-BASED FIRST AND HIGH-ORDER RADIOMIC FEATURES IN DISCRIMINATING SACRAL CHORDOMAS AND CHONDROSARCOMAS WITH OVERLAPPING CONVENTIONAL IMAGING FEATURES
Elvis Duran Sierra
Favorite
(P 356) BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITIES SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Elvis Duran Sierra
Favorite
(P 357) APPARENT DIFFUSION COEFFICIENT (ADC) HIGH-ORDER RADIOMICS OF BASELINE AND POST-TREATMENT ADVANCED MRI OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA.
Elvis Duran Sierra
Favorite
(P 358) CONTRAST-ENHANCED SUSCEPTIBILITY IMAGING (CE-SWI) MORPHOLOGIC, FIRST & HIGH-ORDER RADIOMIC FEATURES VALUE IN ASSESSING TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Elvis Duran Sierra
Favorite
(P 359) ROLE OF PERFUSION WEIGHTED IMAGING WITH DYNAMIC CONTRAST ENHANCED (PWI/DCE) FOR THE TREATMENT ASSESSMENT OF EXTREMITY SOFT-TISSUE NON-MYXOID UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Elvis Duran Sierra
Favorite
Durfee, Cameron

University of Texas Health San Antonio
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Cameron Durfee
Favorite
Duriseti, Sai

UCLA
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Sai Duriseti
Favorite
Dusenbery, Kathryn

University of Minnesota
(P 167) FDG-PET-CT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY PREDICTS LONG-TERM OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA -- 15-YEAR FOLLOW-UP
Kathryn Dusenbery
Favorite
Duus, Nicolas

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and Clinical Cooperation Unit Virotherapy, National Center for Tumor Diseases (NCT) Heidelberg
(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT
Nicolas Duus
Favorite
Du, Xinhui

Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Xinhui Du
Favorite
Du, Xiuping

Department of Medical Oncology, Affiliated Hospital of Xuzhou Medical University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Xiuping Du
Favorite
Du, Yuqiang

Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Yuqiang Du
Favorite
Dyer, Michael

St. Jude Children's Research Hospital
(P 288) EVALUATION OF ATR AND WEE1 INHIBITORS COMBINED WITH NANO-LIPOSOMAL IRINOTECAN IN A LARGE COHORT OF RHABDOMYOSARCOMA XENOGRAFTS USING A TWIN MOUSE PRECLINICAL TRIAL DESIGN
Michael Dyer
Favorite
(P 303) PRECLINICAL EVALUATION OF PARP1 SELECTIVE INHIBITOR AZD5305 IN COMBINATION WITH DNA DAMAGING AGENTS IN EWING SARCOMA ORTHOTOPIC XENOGRAFT MODELS
Michael Dyer
Favorite
Dykema, Karl

Atrium Health Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Karl Dykema
Favorite